Minerva Pharmaceutical S.A.

The US FDA’s user fee calendar for 2024 already features almost 60 new molecular entities and novel biologics, echoing the agency’s review workload at the beginning of 2023 – a position that contains

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Caps Hectic Deal-Making Skein Wit

Mining the "immunome" for cancer markers The problem with cancer is that by the time it is detected, it is usually fairly advanced, and therefore difficult to treat. If it could be picked up earlier,

Each year in the US, an estimated 1.2 million people are diagnosed with cancer. More than half a million died of it in 1999. The disease, which costs the US economy $107 billion per year, according to